{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T08:35:39Z","timestamp":1794040539825,"version":"4.8.0"},"reference-count":266,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000381","name":"Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000381","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.msard.2025.106456","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T02:31:28Z","timestamp":1745029888000},"page":"106456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Brain health \u2013 time matters: multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and related conditions. 2024 report"],"prefix":"10.1016","volume":"101","author":[{"given":"Helmut","family":"Butzkueven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Arkelsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Drulovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Haartsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Helme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Hlav\u00e1cov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Kasilingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00fal","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"de S\u00e8ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitzi J","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":false,"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106456_bib0001","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/MLR.0b013e318268aaff","article-title":"The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy","volume":"50","author":"Ahmed","year":"2012","journal-title":"Med. Care"},{"key":"10.1016\/j.msard.2025.106456_bib0002","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.1038\/s41467-023-42682-9","article-title":"Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis","volume":"14","author":"Akesson","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2025.106456_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102702","article-title":"Experience of South American MS and\/or NMOSD experts in practice during the COVID-19 pandemic: focus on telemedicine","volume":"48","author":"Alonso","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0004","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jamaneurol.2021.3416","article-title":"Health disparities, inequities, and social determinants of health in multiple sclerosis and related disorders in the US: a review","volume":"78","author":"Amezcua","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/11795735241231094","article-title":"Advances in the long-term treatment of neuromyelitis optica spectrum disorder","volume":"16","author":"Anderson","year":"2024","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.msard.2025.106456_bib0006","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/ene.14729","article-title":"Pain, depression, and quality of life in adults with MOG-antibody-associated disease","volume":"28","author":"Asseyer","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0007","unstructured":"Atlas of MS. Healthcare provision. Number of MS specialist neurologists per 100 000 people. https:\/\/www.atlasofms.org\/chart\/united-kingdom\/healthcare-provision\/number-of-ms-specialist-neurologists-per-one-hundred-thousand-people (accessed 17 June 2024a)."},{"key":"10.1016\/j.msard.2025.106456_bib0008","unstructured":"Atlas of MS. Healthcare provision. Number of MS specialist nurses per 100 000 people. https:\/\/www.atlasofms.org\/chart\/united-kingdom\/healthcare-provision\/number-of-ms-nurses-per-one-hundred-thousand-people (accessed 17 June 2024b)."},{"key":"10.1016\/j.msard.2025.106456_bib0009","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41577-022-00718-z","article-title":"The immunology of multiple sclerosis","volume":"22","author":"Attfield","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.msard.2025.106456_bib0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.30699\/fhi.v12i0.395","article-title":"The role of health literacy in multiple sclerosis: a systematic review","volume":"12","author":"Baghini","year":"2023","journal-title":"Front. Health Inform."},{"key":"10.1016\/j.msard.2025.106456_bib0011","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0012","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.molmed.2019.11.003","article-title":"Epstein-Barr virus in multiple sclerosis: theory and emerging immunotherapies","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.msard.2025.106456_bib0013","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/cei.13641","article-title":"Clinical and neuroimaging findings in MOGAD-MRI and OCT","volume":"206","author":"Bartels","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2025.106456_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph181910096","article-title":"Social prescribing and lifestyle medicine \u2013 a remedy to chronic health problems?","volume":"18","author":"Baska","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.msard.2025.106456_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/13524585241265961","article-title":"The first global landscape analysis of multiple sclerosis research funding","author":"Bebo","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0016","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/13524585221075990","article-title":"Pathways to cures for multiple sclerosis: a research roadmap","volume":"28","author":"Bebo","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0017","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/phn.12983","article-title":"Evaluation of the core 5 social determinants of health screening tool","volume":"39","author":"Bechtel","year":"2022","journal-title":"Public Health Nurs."},{"key":"10.1016\/j.msard.2025.106456_bib0018","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106456_bib0019","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2377-12-55","article-title":"Brief International Cognitive Assessment for MS (BICAMS): international standards for validation","volume":"12","author":"Benedict","year":"2012","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0020","unstructured":"Big MS. https:\/\/bigmsdata.org\/(accessed 31 July 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0021","doi-asserted-by":"crossref","first-page":"e2216","DOI":"10.1212\/WNL.0000000000008617","article-title":"Disability worsening among persons with multiple sclerosis and depression: a Swedish cohort study","volume":"93","author":"Binzer","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106456_bib0022","first-page":"725","article-title":"Multiple sclerosis: etiology, symptoms, incidence and prevalence, and implications for community living and employment","volume":"52","author":"Bishop","year":"2015","journal-title":"Work"},{"key":"10.1016\/j.msard.2025.106456_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.554375","article-title":"Effects of menopause in women with multiple sclerosis: an evidence-based review","volume":"12","author":"Bove","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0024","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1017\/S026646232300017X","article-title":"A review of HTA guidelines on societal and novel value elements","volume":"39","author":"Breslau","year":"2023","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"10.1016\/j.msard.2025.106456_bib0025","article-title":"High prevalence of fatigue in contemporary patients with multiple sclerosis","volume":"7","author":"Broch","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106456_bib0026","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40273-023-01307-1","article-title":"Moving forward with taking a societal perspective: a themed issue on productivity costs, consumption costs and informal care costs","volume":"41","author":"Brouwer","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.msard.2025.106456_bib0027","article-title":"Real-world effectiveness of disease-modifying therapies in older adults with multiple sclerosis","volume":"3","author":"Butler","year":"2024","journal-title":"J. Public Health Med."},{"key":"10.1016\/j.msard.2025.106456_bib0028","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/1352458506070775","article-title":"MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis","volume":"12","author":"Butzkueven","year":"2006","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0029","unstructured":"CAN DO Multiple Sclerosis. MS exercises. https:\/\/cando-ms.org\/exercises\/(accessed 6 August 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.851413","article-title":"Disease-modifying drugs and breastfeeding in multiple sclerosis: a narrative literature review","volume":"13","author":"Capone","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0031","unstructured":"Charles Rivers Associates, 2014. Access to medicines for multiple sclerosis: challenges and opportunities. https:\/\/media.crai.com\/wp-content\/uploads\/2020\/09\/16164823\/CRA-Biogen-Access-to-MS-Treatment-Final-Report.pdf (accessed 12 August 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0032","unstructured":"Charles River Associates, 2017. The socioeconomic impact of MS on women in Europe. Available from: https:\/\/www.emdgroup.com\/press-releases\/2017\/oct\/us\/The-socioeconomic-impact-of-MS-on-women-in-Europe-US.pdf (accessed 30 July 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0033","unstructured":"Charles River Associates, 2024. Assessment of the impact of earlier access to disease-modifying treatments with more convenient administration frequency in reducing the socioeconomic burden for multiple sclerosis patients in Europe. https:\/\/media.crai.com\/wp-content\/uploads\/2024\/05\/13145524\/CRA-Merck-The-broader-socioeconomic-impact-of-early-access-to-MCAF-treatments-in-MS.pdf (accessed 06 July 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0034","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/jnnp-2018-318228","article-title":"Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data","volume":"89","author":"Chen","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106456_bib0035","article-title":"The distinction of area postrema syndrome between MOGAD and NMOSD","volume":"10","author":"Chen","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.msard.2025.106456_bib0036","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cei.13630","article-title":"Magnetic resonance imaging in neuromyelitis optica spectrum disorder","volume":"206","author":"Clarke","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2025.106456_bib0037","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00415-017-8583-z","article-title":"MOG antibody-related disorders: common features and uncommon presentations","volume":"264","author":"Cobo-Calvo","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0038","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1473-3099(22)00066-4","article-title":"Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review","volume":"22","author":"Crawshaw","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.msard.2025.106456_bib0039","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2589-7500(22)00252-7","article-title":"Embedding patient-reported outcomes at the heart of artificial intelligence health-care technologies","volume":"5","author":"Cruz Rivera","year":"2023","journal-title":"Lancet Digit. Health"},{"key":"10.1016\/j.msard.2025.106456_bib0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.12688\/f1000research.13284.1","article-title":"Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays?","volume":"7","author":"Culyer","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.msard.2025.106456_bib0041","first-page":"247","article-title":"Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action","volume":"7","author":"Damal","year":"2013","journal-title":"Biologics"},{"key":"10.1016\/j.msard.2025.106456_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.914338","article-title":"Valuing the \u201cburden\u201d and impact of rare diseases: a scoping review","volume":"13","author":"Delaye","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.msard.2025.106456_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.966428","article-title":"The patient journey with NMOSD: from initial diagnosis to chronic condition","volume":"13","author":"Delgado-Garcia","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0044","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1212\/WNL.0000000000004763","article-title":"Costs of informal nursing care for patients with neurologic disorders: a systematic review","volume":"90","author":"Diederich","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106456_bib0045","article-title":"The socioeconomic impact of disability progression in multiple sclerosis: a retrospective cohort study of the German NeuroTransData (NTD) registry","volume":"9","author":"Dillon","year":"2023","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106456_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.866824","article-title":"Serum and cerebrospinal fluid biomarkers in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disease","volume":"13","author":"Dinoto","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0047","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","article-title":"UK consensus on pregnancy in multiple sclerosis: association of British Neurologists' guidelines","volume":"19","author":"Dobson","year":"2019","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0048","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis \u2013 a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0049","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S1474-4422(22)00005-9","article-title":"Social determinants of neurological disease: tackling inequalities","volume":"21","author":"Dobson","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0050","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41582-022-00735-5","article-title":"Social determinants of health in multiple sclerosis","volume":"18","author":"Dobson","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0051","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ana.26858","article-title":"Time to disability milestones and annualized relapse rates in NMOSD and MOGAD","volume":"95","author":"Duchow","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0052","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.msard.2017.06.003","article-title":"The effect of exercise training in adults with multiple sclerosis with severe mobility disability: a systematic review and future research directions","volume":"16","author":"Edwards","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0053","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1007\/s00415-022-11249-x","article-title":"Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy","volume":"269","author":"Eid","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159129","article-title":"Cost of illness of multiple sclerosis \u2013 a systematic review","volume":"11","author":"Ernstsson","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2025.106456_bib0055","doi-asserted-by":"crossref","first-page":"124","DOI":"10.7224\/1537-2073.2021-019","article-title":"Sleep quality in neuromyelitis optica spectrum disorder: a systematic review","volume":"24","author":"Eshtiaghi","year":"2022","journal-title":"Int. J. MS Care."},{"key":"10.1016\/j.msard.2025.106456_bib0056","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0300777","article-title":"The psychological burden of NMOSD \u2013 a mixed method study of patients and caregivers","volume":"19","author":"Esiason","year":"2024","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2025.106456_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105682","article-title":"The diagnostic performance of AI-based algorithms to discriminate between NMOSD and MS using MRI features: a systematic review and meta-analysis","volume":"87","author":"Etemadifar","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0058","unstructured":"European Committee for Treatment and Research in Multiple Sclerosis, 2024. The impact of ageing on multiple sclerosis. https:\/\/ectrims.eu\/insights\/the-impact-of-ageing-on-multiple-sclerosis\/(accessed 3 September 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0059","unstructured":"European Multiple Sclerosis Platform, 2021. MS Barometer 2020. https:\/\/barometer.ams3.digitaloceanspaces.com\/55ac809262a6e9ad124ecb0dc813d225.pdf (accessed 16 June 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0060","unstructured":"European Multiple Sclerosis Platform, 2022. Impact of multiple sclerosis symptoms. https:\/\/emsp.org\/projects\/impact-of-multiple-sclerosis-symptoms-imss\/(accessed 22 August 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0062","article-title":"Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder","volume":"427","author":"Exuzides","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106456_bib0063","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1379538","article-title":"Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review","volume":"15","author":"Fernandez","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106456_bib0064","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.642384","article-title":"The evolution of neurofilament light chain in multiple sclerosis","volume":"15","author":"Ferreira-Atuesta","year":"2021","journal-title":"Front. Neurosci."},{"issue":"Suppl 5","key":"10.1016\/j.msard.2025.106456_bib0065","doi-asserted-by":"crossref","first-page":"v16","DOI":"10.1007\/s00415-005-5004-5","article-title":"MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system","volume":"252","author":"Filippi","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0066","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"Suppl. 1","key":"10.1016\/j.msard.2025.106456_bib0067","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/eurpub\/ckw255","volume":"27","author":"Fjaer","year":"2017","journal-title":"Eur. J. Public Health"},{"key":"10.1016\/j.msard.2025.106456_bib0068","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0069","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/13524585231197926","article-title":"Intimate partner violence and multiple sclerosis","volume":"30","author":"Freedman","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0070","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1017\/S0317167100014244","article-title":"Treatment optimization in MS: Canadian MS Working Group updated recommendations","volume":"40","author":"Freedman","year":"2013","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106456_bib0071","first-page":"1","article-title":"Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell J."},{"key":"10.1016\/j.msard.2025.106456_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105376","article-title":"Measuring the economic burden of neuromyelitis optica spectrum disorder in Colombia","volume":"82","author":"Gil-Rojas","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"Suppl. 1","key":"10.1016\/j.msard.2025.106456_bib0073","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","article-title":"Brain health: time matters in multiple sclerosis","volume":"9","author":"Giovannoni","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0074","article-title":"MS care: integrating advanced therapies and holistic management","volume":"14","author":"Giovannoni","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0075","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211066751","article-title":"Smouldering multiple sclerosis: the 'real MS","volume":"15","author":"Giovannoni","year":"2022","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0076","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1756285610385608","article-title":"Evolving expectations around early management of multiple sclerosis","volume":"3","author":"Gold","year":"2010","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0077","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1169400","article-title":"The therapeutic value of treatment for multiple sclerosis: analysis of health technology assessments of three European countries","volume":"14","author":"Gozzo","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.msard.2025.106456_bib0078","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200253","article-title":"Practical considerations for managing pregnancy in patients with multiple sclerosis: dispelling the myths","volume":"14","author":"Graham","year":"2024","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.msard.2025.106456_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103289","article-title":"Improving smoking cessation support for people with multiple sclerosis: a qualitative analysis of clinicians' views and current practice","volume":"56","author":"Grech","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0080","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.socscimed.2007.03.007","article-title":"Biographical disruption associated with multiple sclerosis: using propensity scoring to assess the impact","volume":"65","author":"Green","year":"2007","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.msard.2025.106456_bib0081","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7224\/1537-2073-13.3.137","article-title":"Monitoring my multiple sclerosis: a patient-administered health-assessment scale","volume":"13","author":"Gulick","year":"2011","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2025.106456_bib0082","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7224\/1537-2073.2016-044","article-title":"Projecting the adequacy of the multiple sclerosis neurologist workforce","volume":"20","author":"Halpern","year":"2018","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2025.106456_bib0083","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/1352458510362441","article-title":"The McDonald Criteria for Multiple Sclerosis: time for clarification","volume":"16","author":"Hawkes","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0084","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jval.2016.01.002","article-title":"Health utilities for multiple sclerosis","volume":"19","author":"Hawton","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2025.106456_bib0085","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0086","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.pmr.2013.06.007","article-title":"Caregiving in multiple sclerosis","volume":"24","author":"Hillman","year":"2013","journal-title":"Phys. Med. Rehabil. Clin. N. Am."},{"issue":"8","key":"10.1016\/j.msard.2025.106456_bib0087","first-page":"822","article-title":"Factors associated with patient preferences for disease-modifying therapies in multiple sclerosis","volume":"23","author":"Hincapie","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.msard.2025.106456_bib0088","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/acn3.52021","article-title":"Impact of neuromyelitis optica spectrum disorder on employment and income in the United States","volume":"11","author":"Hjerthen","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0089","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1177\/1352458518809326","article-title":"International consensus on quality standards for brain health-focused care in multiple sclerosis","volume":"25","author":"Hobart","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0090","article-title":"Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): development of a globally applicable quality improvement tool","volume":"8","author":"Hobart","year":"2022","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106456_bib0091","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1073\/pnas.1516047113","article-title":"Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whites","volume":"113","author":"Hoffman","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.msard.2025.106456_bib0092","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2147\/PPA.S452849","article-title":"Preferences, adherence, and satisfaction: three years of treatment experiences of people with multiple sclerosis","volume":"18","author":"Hoffmann","year":"2024","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2025.106456_bib0093","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/cts.13492","article-title":"Synergy between health technology assessments and clinical guidelines for multiple sclerosis","volume":"16","author":"Hogervorst","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.msard.2025.106456_bib0094","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jns.2016.01.010","article-title":"Cognition, mood, and purpose in life in neuromyelitis optica spectrum disorder","volume":"362","author":"Hollinger","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106456_bib0095","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.msard.2019.05.013","article-title":"Neuromyelitis optica testing and treatment: availability and affordability in 60 countries","volume":"33","author":"Holroyd","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0096","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/ICU.0000000000000703","article-title":"Update on neuromyelitis optica spectrum disorder","volume":"31","author":"Holroyd","year":"2020","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.msard.2025.106456_bib0097","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0098","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1260358","article-title":"Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide","volume":"14","author":"Hor","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0099","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/ncn3.12478","article-title":"Neuromyelitis optica spectrum disorder in Asia: epidemiology and risk factors","volume":"9","author":"Hor","year":"2021","journal-title":"Neurol. Clin. Neurosci."},{"key":"10.1016\/j.msard.2025.106456_bib0100","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s13311-011-0065-x","article-title":"Myelin regeneration in multiple sclerosis: targeting endogenous stem cells","volume":"8","author":"Huang","year":"2011","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2025.106456_bib0101","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13023-022-02310-z","article-title":"Health utilities and costs for neuromyelitis optica spectrum disorder","volume":"17","author":"Hughes","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.msard.2025.106456_bib0102","doi-asserted-by":"crossref","first-page":"e1184","DOI":"10.1212\/WNL.0000000000200052","article-title":"Costs and health-related quality of life in patients with NMO spectrum disorders and MOG-antibody-associated disease: CHANCE(NMO) Study","volume":"98","author":"Hummert","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106456_bib0061","doi-asserted-by":"crossref","unstructured":"Husereau, D., Drummond, M., Augustovski, F. et al. 2022. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 20, 23. DOI:10.1186\/s12916-021-02204-0.","DOI":"10.1186\/s12916-021-02204-0"},{"key":"10.1016\/j.msard.2025.106456_bib0103","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3988\/jcn.2020.16.1.124","article-title":"Comparison of neuropathic pain in neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"16","author":"Hyun","year":"2020","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0104","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211019574","article-title":"Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies","volume":"14","author":"Iaffaldano","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0105","unstructured":"Institute of Health Equity, 2020. Marmot review 10 years on. https:\/\/www.instituteofhealthequity.org\/resources-reports\/marmot-review-10-years-on (accessed 13 June 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0106","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.845539","article-title":"A quantitative synthesis of eight decades of global multiple sclerosis research using bibliometrics","volume":"13","author":"Ismail","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0107","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.msard.2025.106456_bib0108","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106456_bib0109","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.euroneuro.2011.05.001","article-title":"The socioeconomic consequences of multiple sclerosis: a controlled national study","volume":"22","author":"Jennum","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.msard.2025.106456_bib0110","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1038\/s41433-024-03108-y","article-title":"MOG antibody-associated optic neuritis","volume":"38","author":"Jeyakumar","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.msard.2025.106456_bib0111","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00415-015-7796-2","article-title":"Epidemiology of multiple sclerosis: results from a large observational study in the UK","volume":"262","author":"Jick","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0112","series-title":"Multiple Sclerosis: Current Status and Strategies for the Future","article-title":"Building and supporting the research enterprise","author":"Joy","year":"2001"},{"key":"10.1016\/j.msard.2025.106456_bib0113","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1478-4491-12-75","article-title":"Global medical education partnerships to expand specialty expertise: a case report on building neurology clinical and research capacity","volume":"12","author":"Kaddumukasa","year":"2014","journal-title":"Hum. Resour. Health"},{"key":"10.1016\/j.msard.2025.106456_bib0114","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1177\/1352458520915629","article-title":"Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course","volume":"26","author":"Kalb","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0115","first-page":"181","article-title":"Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis","volume":"87","author":"Kappus","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106456_bib0116","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/ane.13411","article-title":"Socioeconomic consequences of multiple sclerosis \u2013 a systematic literature review","volume":"143","author":"Kavaliunas","year":"2021","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2025.106456_bib0117","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105596","article-title":"Cognitive and psychopathological features of neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease: a narrative review","volume":"85","author":"Kazzi","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0118","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/PPA.S440410","article-title":"Shared decision-making in the treatment of multiple sclerosis: results of a cross-sectional, real-world survey in Europe and the United States","volume":"18","author":"Keenan","year":"2024","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2025.106456_bib0119","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12883-020-01736-x","article-title":"A self-administered, artificial intelligence (AI) platform for cognitive assessment in multiple sclerosis (MS)","volume":"20","author":"Khaligh-Razavi","year":"2020","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0120","doi-asserted-by":"crossref","first-page":"754","DOI":"10.12968\/bjon.2020.29.13.754","article-title":"What barriers prevent health professionals screening women for domestic abuse? A literature review","volume":"29","author":"Kirk","year":"2020","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.msard.2025.106456_bib0121","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1212\/CPJ.0000000000001105","article-title":"How multiple sclerosis symptoms vary by age, sex, and race\/ethnicity","volume":"11","author":"Kister","year":"2021","journal-title":"Neurol. Clin. Pract."},{"issue":"Pt 6","key":"10.1016\/j.msard.2025.106456_bib0122","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106456_bib0123","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0124","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40120-021-00311-x","article-title":"Evaluating the economic burden of relapses in neuromyelitis optica spectrum disorder: a real-world analysis using German claims data","volume":"11","author":"Knapp","year":"2022","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106456_bib0125","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","article-title":"New insights into the burden and costs of multiple sclerosis in Europe","volume":"23","author":"Kobelt","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0126","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2013 revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"Kumpfel","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0127","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106456_bib0128","article-title":"Fatigue is a common symptom in myelin oligodendrocyte glycoprotein antibody disease","volume":"8","author":"Ladakis","year":"2022","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106456_bib0129","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","article-title":"Ocrelizumab: a review in multiple sclerosis","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2025.106456_bib0130","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/1352458511431076","article-title":"Recommendations for a brief international cognitive assessment for Multiple Sclerosis (BICAMS)","volume":"18","author":"Langdon","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0131","doi-asserted-by":"crossref","first-page":"e1939","DOI":"10.1212\/WNL.0000000000009374","article-title":"Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort","volume":"94","author":"Langer-Gould","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106456_bib0132","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105007","article-title":"The prevalence of depression, anxiety, and sleep disturbances in patients with neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis","volume":"79","author":"Liu","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0133","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/jnnp-2023-332851","article-title":"The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease","volume":"95","author":"Liyanage","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106456_bib0134","first-page":"1653","article-title":"Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature","volume":"8","author":"Lizan","year":"2014","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2025.106456_bib0135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/IJWH.S334719","article-title":"Impact of menopause in patients with multiple sclerosis: current perspectives","volume":"15","author":"Lorefice","year":"2023","journal-title":"Int. J. Womens Health"},{"key":"10.1016\/j.msard.2025.106456_bib0136","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12939-020-01375-1","article-title":"Socioeconomic inequalities in primary-care and specialist physician visits: a systematic review","volume":"20","author":"Lueckmann","year":"2021","journal-title":"Int. J. Equity Health"},{"key":"10.1016\/j.msard.2025.106456_bib0137","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3389\/fneur.2020.00851","article-title":"Comorbidity in multiple sclerosis","volume":"11","author":"Magyari","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0138","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41582-020-0313-y","article-title":"Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations","volume":"16","author":"Mao-Draayer","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0139","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/vaccines8010035","article-title":"Cytomegalovirus and Epstein-Barr virus associations with neurological diseases and the need for vaccine development","volume":"8","author":"Maple","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.msard.2025.106456_bib0140","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrneurol.2017.33","article-title":"Comorbidity in multiple sclerosis: implications for patient care","volume":"13","author":"Marrie","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0141","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1212\/CPJ.0000000000001167","article-title":"Disparities in telehealth care in multiple sclerosis","volume":"12","author":"Marrie","year":"2022","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.msard.2025.106456_bib0142","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1142640","article-title":"Understanding the employment impact of neuromyelitis optica spectrum disorder in the USA: mixed methods","volume":"14","author":"Mateen","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0143","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1111\/jgs.17269","article-title":"Caregiver economics: a framework for estimating the value of the American Jobs Plan for a caring infrastructure","volume":"69","author":"Mattingly","year":"2021","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.msard.2025.106456_bib0144","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41591-023-02224-8","article-title":"Patient wisdom should be incorporated into health AI to avoid algorithmic paternalism","volume":"29","author":"McCradden","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2025.106456_bib0145","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2025.106456_bib0146","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.autrev.2017.04.010","article-title":"Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review","volume":"16","author":"Merkel","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2025.106456_bib0147","doi-asserted-by":"crossref","first-page":"e2020","DOI":"10.1212\/WNL.0000000000012850","article-title":"Association between cognitive trajectories and disability progression in patients with relapsing-remitting multiple sclerosis","volume":"97","author":"Merlo","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106456_bib0148","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1177\/1352458518798147","article-title":"Silent lesions on MRI imaging \u2013 shifting goal posts for treatment decisions in multiple sclerosis","volume":"24","author":"Min","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0149","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011142","article-title":"Patient-reported outcome measure for neuromyelitis optica: pretesting of preliminary instrument and protocol for further development in accordance with international guidelines","volume":"6","author":"Moore","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.msard.2025.106456_bib0150","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1177\/13524585231197056","article-title":"Well-being at midlife: correlates of mental health in ambulatory menopausal women with multiple sclerosis","volume":"29","author":"Morales-Rodriguez","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0151","unstructured":"MS Australia, 2023. Health economic impact of multiple sclerosis in Australia in 2021: an interim update of prevalence, costs and cost of illness from 2017 to 2021. https:\/\/www.msaustralia.org.au\/wp-content\/uploads\/2023\/02\/health-economic-impact-of-multiple-sclerosis-in-australia-in-2021_final.pdf (accessed 22 June 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0152","unstructured":"MS Brain Health, 2015. Brain health: time matters in multiple sclerosis. https:\/\/www.msbrainhealth.org\/wp-content\/uploads\/2021\/05\/brain-health-time-matters-in-multiple-sclerosispolicy-report.pdf (accessed 5 September 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0154","unstructured":"MS International Federation, 2020. Atlas of MS 3rd edition. Part 1: mapping multiple sclerosis around the world \u2013 key epidemiology findings. https:\/\/www.msif.org\/wp-content\/uploads\/2020\/12\/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf (accessed 25 August 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0155","unstructured":"MS International Federation, 2021. Atlas of MS 3rd edition. Part 2: clinical management of multiple sclerosis around the world. https:\/\/www.msif.org\/wp-content\/uploads\/2021\/05\/Atlas-3rd-Edition-clinical-management-report-EN-5-5-21.pdf (accessed 25 August 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0156","unstructured":"MS International Federation. About MS. https:\/\/www.msif.org\/about-ms\/(accessed 2 August 2024a)."},{"key":"10.1016\/j.msard.2025.106456_bib0157","unstructured":"MS International Federation. Awards, grants and fellowships. https:\/\/www.msif.org\/research\/awards-grants-and-fellowships\/(accessed 12 August 2024b)."},{"key":"10.1016\/j.msard.2025.106456_bib0158","unstructured":"MS Nurse PRO. https:\/\/msnursepro.org\/(accessed 2 August 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0159","unstructured":"MS Research Flagship. MS WorkSmart. https:\/\/msresearchflagship.org.au\/community\/ms-worksmart (accessed 30 July 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0160","unstructured":"MS Selfie Microsite, 2024. How can I reduce my chances of adverse events on specific DMTs? https:\/\/msselfie.co.uk\/monitoring-ms\/how-can-i-reduce-my-chances-of-adverse-events-on-specific-dmts\/(accessed 4 July 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0161","unstructured":"MS Society, 2020a. MS enough: make welfare make sense. https:\/\/www.mssociety.org.uk\/sites\/default\/files\/2020-08\/MS-Enough-report.pdf (accessed 6 August 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0162","unstructured":"MS Society, 2020b. My MS my needs survey 2019: UK findings. https:\/\/www.mssociety.org.uk\/sites\/default\/files\/2020-08\/MMMN3-UK-report.pdf (accessed 6 August 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib1162","unstructured":"MS Society. Early signs of MS. https:\/\/www.mssociety.org.uk\/about-ms\/signs-and-symptoms\/early-signs-of-ms (accessed 29 July 2024a)."},{"key":"10.1016\/j.msard.2025.106456_bib0165","unstructured":"MS Society. Exercises for MS symptoms. https:\/\/www.mssociety.org.uk\/living-with-ms\/physical-and-mental-health\/staying-active\/exercises-for-ms-symptoms (accessed 6 August 2024b)."},{"key":"10.1016\/j.msard.2025.106456_bib0163","unstructured":"MS Society. https:\/\/www.mssociety.org.uk\/(accessed 2 August 2024c)."},{"key":"10.1016\/j.msard.2025.106456_bib0166","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1080\/09638288.2016.1193233","article-title":"If they are OK, we are OK: the experience of partners living with neuromyelitis optica","volume":"39","author":"Mutch","year":"2017","journal-title":"Disabil. Rehabil."},{"key":"10.1016\/j.msard.2025.106456_bib0167","unstructured":"National Institute for Health and Care Excellence, 2022. Evidence reviews for coordination of care: the role of MS nurse specialists and other healthcare professionals. Multiple sclerosis in adults: management. Evidence review B. NICE Guideline, No. 220 https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK585276\/(accessed 3 September 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0168","unstructured":"National Multiple Sclerosis Society, 2022. Access to high quality MS healthcare principles. https:\/\/www.nationalmssociety.org\/Get-Involved\/Advocate-for-Change\/Take-Action\/Access-to-High-Quality-Healthcare\/Access-to-High-Quality-MS-Healthcare-Principles (accessed 13 June 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0169","unstructured":"National Multiple Sclerosis Society, 2023. Understanding myelin oligodendrocyte glycoprotein antibody disease (MOGAD). https:\/\/www.nationalmssociety.org\/understanding-ms\/what-is-ms\/related-conditions\/mogad (accessed 29 July 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0170","unstructured":"National Multiple Sclerosis Society, 2024a. Multiple sclerosis symptoms. https:\/\/www.nationalmssociety.org\/understanding-ms\/what-is-ms\/ms-symptoms (accessed 25 August 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0171","unstructured":"National Multiple Sclerosis Society. Raise awareness. https:\/\/www.nationalmssociety.org\/how-you-can-help\/get-involved\/raise-awareness (accessed 2 August 2024b)."},{"key":"10.1016\/j.msard.2025.106456_bib0172","unstructured":"Neurology Academy. Multiple Sclerosis Academy. https:\/\/neurologyacademy.org\/ms-academy (accessed 2 August 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0173","unstructured":"NHS England. Social prescribing. https:\/\/www.england.nhs.uk\/personalisedcare\/social-prescribing\/(accessed 30 July 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0174","article-title":"Personal and societal costs of multiple sclerosis in the UK: a population-based MS registry study","volume":"6","author":"Nicholas","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106456_bib0175","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1212\/WNL.53.5.1098","article-title":"Quality of life in multiple sclerosis: measuring the disease effects more broadly","volume":"53","author":"Nortvedt","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106456_bib0176","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s13311-017-0571-6","article-title":"Evolution of patient-reported outcomes and their role in multiple sclerosis clinical trials","volume":"14","author":"Nowinski","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2025.106456_bib0177","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3389\/fneur.2019.00608","article-title":"Cognitive impairment in neuromyelitis optica spectrum disorders: a review of clinical and neuroradiological features","volume":"10","author":"Oertel","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0178","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/460825","article-title":"Neuromyelitis optica: an antibody-mediated disorder of the central nervous system","author":"Oh","year":"2012","journal-title":"Neurol. Res. Int."},{"key":"10.1016\/j.msard.2025.106456_bib0179","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/11592160-000000000-00000","article-title":"Burden of a multiple sclerosis relapse: the patient's perspective","volume":"5","author":"Oleen-Burkey","year":"2012","journal-title":"Patient"},{"key":"10.1016\/j.msard.2025.106456_bib0180","first-page":"352","article-title":"Quality of life in multiple sclerosis","volume":"3","author":"Opara","year":"2010","journal-title":"J. Med. Life"},{"key":"10.1016\/j.msard.2025.106456_bib0181","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","article-title":"The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK","volume":"10","author":"Orme","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2025.106456_bib0182","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2147\/NDT.S68389","article-title":"Association between smoking and cognitive impairment in multiple sclerosis","volume":"10","author":"Ozcan","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.msard.2025.106456_bib0183","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0184","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1038\/s41433-023-02478-z","article-title":"Evaluating patient-reported outcome measures (PROMs) for future clinical trials in adult patients with optic neuritis","volume":"37","author":"Panthagani","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.msard.2025.106456_bib0185","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106456_bib0186","article-title":"Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study)","author":"Passoke","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.msard.2025.106456_bib0187","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/13524585241228739","article-title":"VISIBL-MS: a bilingual educational framework to increase awareness of early multiple sclerosis","volume":"30","author":"Patel","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0188","unstructured":"Patient Reported Outcomes for Multiple Sclerosis. https:\/\/proms-initiative.org\/(accessed 22 August 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0189","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029058","article-title":"Biomarkers in multiple sclerosis","volume":"9","author":"Paul","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.msard.2025.106456_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102162","article-title":"A literature review of cost-of-illness studies on the economic burden of multiple sclerosis","volume":"43","author":"Paz-Zulueta","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0191","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102634","article-title":"Multiple Sclerosis Data Alliance \u2013 a global multi-stakeholder collaboration to scale-up real world data research","volume":"47","author":"Peeters","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0192","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2486\/indhealth.2017-0214","article-title":"Improving the job-retention strategies in multiple sclerosis workers: the role of occupational physicians","volume":"57","author":"Persechino","year":"2019","journal-title":"Ind. Health"},{"key":"10.1016\/j.msard.2025.106456_bib0193","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3988\/jcn.2019.15.1.77","article-title":"Quality of life and emotional strain in caregivers of patients with multiple sclerosis","volume":"15","author":"Petrikis","year":"2019","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0194","doi-asserted-by":"crossref","DOI":"10.2196\/48030","article-title":"The journey of data within a global data sharing initiative: a federated 3-layer data analysis pipeline to scale up multiple sclerosis research","volume":"11","author":"Pirmani","year":"2023","journal-title":"JMIR Med. Inform."},{"key":"10.1016\/j.msard.2025.106456_bib0195","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00415-009-0120-2","article-title":"Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis","volume":"256","author":"Pittas","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0196","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/ene.12715","article-title":"Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis","volume":"23","author":"Planche","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0197","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/13524585221122169","article-title":"MeTooMS: sexual, physical, and emotional abuse experience among women with multiple sclerosis","volume":"29","author":"Pol-Patil","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0198","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/neurosci3040048","article-title":"Cognitive impairment in multiple sclerosis: an update on assessment and management","volume":"3","author":"Portaccio","year":"2022","journal-title":"NeuroSci"},{"key":"10.1016\/j.msard.2025.106456_bib0199","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.brainres.2009.06.063","article-title":"Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis","volume":"1341","author":"Prakash","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.msard.2025.106456_bib0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612631","article-title":"Smouldering lesion in MS: microglia, lymphocytes and pathobiochemical mechanisms","volume":"24","author":"Pukoli","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2025.106456_bib0201","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s12883-021-02396-1","article-title":"Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review","volume":"21","author":"Ramirez","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0202","unstructured":"RAND Europe, 2019. Exploring the societal burden of multiple sclerosis. https:\/\/www.rand.org\/pubs\/research_reports\/RR4262.html (accessed 6 August 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0203","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/nyas.15171","article-title":"Global outlook on affordability of biotherapeutic drugs","volume":"1537","author":"Rathore","year":"2024","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.msard.2025.106456_bib0204","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s13311-022-01206-x","article-title":"Monoclonal antibody therapies beyond complement for NMOSD and MOGAD","volume":"19","author":"Redenbaugh","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2025.106456_bib0206","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102024","article-title":"Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis","volume":"41","author":"Reyes","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0205","doi-asserted-by":"crossref","first-page":"e880","DOI":"10.1212\/NXI.0000000000000880","article-title":"CSF neurofilament light chain testing as an aid to determine treatment strategies in MS","volume":"7","author":"Reyes","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106456_bib0207","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10198-022-01471-9","article-title":"Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease","volume":"24","author":"Rodriguez-Sanchez","year":"2023","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.msard.2025.106456_bib0208","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/13524585231164295","article-title":"Employment status, productivity loss, and associated factors among people with multiple sclerosis","volume":"29","author":"Rodriguez Llorian","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0209","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/01616412.2021.1949686","article-title":"Multiple sclerosis and neuromyelitis optica spectrum disorder testing and treatment availability in Latin America","volume":"43","author":"Rojas","year":"2021","journal-title":"Neurol. Res."},{"key":"10.1016\/j.msard.2025.106456_bib0210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1212\/CPJ.0000000000001152","article-title":"Fast Neuro: a care model to expedite access to neurology clinic","volume":"12","author":"Roy","year":"2022","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.msard.2025.106456_bib0211","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40120-021-00253-4","article-title":"Neuromyelitis optica spectrum disorder: clinical burden and cost of relapses and disease-related care in US clinical practice","volume":"10","author":"Royston","year":"2021","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106456_bib0212","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2025.106456_bib0213","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s40120-023-00474-9","article-title":"Patient pathway to diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): findings from a multinational survey of 204 patients","volume":"12","author":"Santoro","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106456_bib0214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgaa764","article-title":"The menopause transition: signs, symptoms, and management options","volume":"106","author":"Santoro","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.msard.2025.106456_bib0215","first-page":"1354","article-title":"Economic burden of multiple sclerosis in the United States: a systematic literature review","volume":"29","author":"Schauf","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.msard.2025.106456_bib0216","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MRR.0b013e32835c79ea","article-title":"Factors related to difficulties with employment in patients with multiple sclerosis: a review of 2002-2011 literature","volume":"36","author":"Schiavolin","year":"2013","journal-title":"Int. J. Rehabil. Res."},{"key":"10.1016\/j.msard.2025.106456_bib0217","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14737167.2022.1987218","article-title":"Cost of illness in multiple sclerosis by disease characteristics \u2013 a review of reviews","volume":"22","author":"Schriefer","year":"2022","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.msard.2025.106456_bib0218","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0219","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","article-title":"Multiple sclerosis: time for early treatment with high-efficacy drugs","volume":"271","author":"Selmaj","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177230","article-title":"Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life","volume":"12","author":"Seok","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2025.106456_bib0221","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.1015256","article-title":"Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies","volume":"13","author":"Simoens","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0222","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12962-024-00552-1","article-title":"An overview of the perspectives used in health economic evaluations","volume":"22","author":"Sittimart","year":"2024","journal-title":"Cost Eff. Resour. Alloc."},{"key":"10.1016\/j.msard.2025.106456_bib0223","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104498","article-title":"Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder","volume":"70","author":"Smith","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0224","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1352458518807082","article-title":"The multiple sclerosis care unit","volume":"25","author":"Soelberg Sorensen","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0225","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","article-title":"Epstein-Barr virus and multiple sclerosis","volume":"21","author":"Soldan","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.msard.2025.106456_bib0226","doi-asserted-by":"crossref","first-page":"e624","DOI":"10.1212\/WNL.0000000000207481","article-title":"Global barriers to the diagnosis of multiple sclerosis: data from the Multiple Sclerosis International Federation Atlas of MS","volume":"101","author":"Solomon","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106456_bib0227","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.0000000000006583","article-title":"Misdiagnosis of multiple sclerosis: impact of the 2017 McDonald criteria on clinical practice","volume":"92","author":"Solomon","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106456_bib0228","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40120-023-00573-7","article-title":"Insights for healthcare providers on shared decision-making in multiple sclerosis: a narrative review","volume":"13","author":"Stoll","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106456_bib0229","doi-asserted-by":"crossref","first-page":"59","DOI":"10.7224\/1537-2073.2019-068","article-title":"Experiences of African American women with multiple sclerosis","volume":"23","author":"Stuifbergen","year":"2021","journal-title":"Int. J. MS Care."},{"key":"10.1016\/j.msard.2025.106456_bib0230","unstructured":"Sumaira Foundation, 2023. Impact of NMOSD on employment: a global survey. https:\/\/www.sumairafoundation.org\/wp-content\/uploads\/2023\/02\/P320_TrapagaHacker.pdf (accessed 15 June 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0231","unstructured":"Sumaira Foundation. https:\/\/www.sumairafoundation.org\/(accessed 2 August 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0232","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3390\/brainsci12070885","article-title":"NMOSD-diagnostic dilemmas leading towards final diagnosis","volume":"12","author":"Szewczyk","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.msard.2025.106456_bib0233","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2023.1130231","article-title":"Cognitive rehabilitation in multiple sclerosis: three digital ingredients to address current and future priorities","volume":"17","author":"Tacchino","year":"2023","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.msard.2025.106456_bib0234","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(23)00041-8","article-title":"Towards equitable access to treatment for multiple sclerosis","volume":"22","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0235","first-page":"239","article-title":"Polypharmacy in multiple sclerosis: current knowledge and future directions","volume":"118","author":"Thelen","year":"2021","journal-title":"Mo Med."},{"key":"10.1016\/j.msard.2025.106456_bib0236","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0237","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/sjopt.sjopt_102_23","article-title":"Monoclonal antibody therapies for aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"38","author":"Tisavipat","year":"2024","journal-title":"Saudi J. Ophthalmol."},{"key":"10.1016\/j.msard.2025.106456_bib0238","unstructured":"UK National Health Service, 2022. Multiple sclerosis overview. https:\/\/www.nhs.uk\/conditions\/multiple-sclerosis\/(accessed 29 July 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0239","unstructured":"UK National Health Service, 2023. Neuromyelitis optica. https:\/\/www.nhs.uk\/conditions\/neuromyelitis-optica\/(accessed 29 July 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104114","article-title":"Risk factors associated with permanent disability in neuromyelitis optica spectrum disorders","volume":"68","author":"Valdivia-Tangarife","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0241","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40268-023-00434-6","article-title":"The benefits and risks of switching from fingolimod to siponimod for the treatment of relapsing-remitting and secondary progressive multiple sclerosis","volume":"23","author":"Valis","year":"2023","journal-title":"Drugs R D"},{"key":"10.1016\/j.msard.2025.106456_bib0242","doi-asserted-by":"crossref","first-page":"230","DOI":"10.5694\/mja2.50113","article-title":"Family planning, antenatal and post partum care in multiple sclerosis: a review and update","volume":"211","author":"Van Der Walt","year":"2019","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.msard.2025.106456_bib0243","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105555","article-title":"Multi-actor system dynamics in access to disease-modifying treatments for multiple sclerosis in Southeast Asia: a regional survey and suggestions for improvement","volume":"85","author":"Viswanathan","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0244","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-058948","article-title":"Occupational outcomes of people with multiple sclerosis: a scoping review","volume":"12","author":"Vitturi","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.msard.2025.106456_bib0245","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1212\/CPJ.0000000000001045","article-title":"Multiple sclerosis phenotypes as a continuum: the role of neurologic reserve","volume":"11","author":"Vollmer","year":"2021","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.msard.2025.106456_bib0246","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/13524585221129472","article-title":"Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society","volume":"29","author":"Vukusic","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0247","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/1352458519843055","article-title":"Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: clinical study data and 5 years of post-marketing experience","volume":"26","author":"Vukusic","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0248","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106456_bib0249","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103445","article-title":"Social participation and quality of life among patients with neuromyelitis optica spectrum disorders: the mediating effects of depression","volume":"57","author":"Wang","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106456_bib0250","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1212\/WNL.0000000000001520","article-title":"Challenges and opportunities in designing clinical trials for neuromyelitis optica","volume":"84","author":"Weinshenker","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106456_bib0251","first-page":"13","article-title":"Multiple sclerosis: systemic challenges to cost-effective care","volume":"15","author":"Weinstein","year":"2022","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.msard.2025.106456_bib0252","doi-asserted-by":"crossref","first-page":"282","DOI":"10.7224\/1537-2073.2018-083","article-title":"Toward digital self-monitoring of multiple sclerosis: investigating first experiences, needs, and wishes of people with MS","volume":"21","author":"Wendrich","year":"2019","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2025.106456_bib0253","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16210","article-title":"Towards new perspectives: a scoping review and meta-synthesis to redefine brain health for multiple sclerosis","volume":"31","author":"Wills","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0254","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"12\u2013a Suppl","key":"10.1016\/j.msard.2025.106456_bib0255","first-page":"S3","article-title":"Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder","volume":"28","author":"Wingerchuk","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.msard.2025.106456_bib0256","unstructured":"Women's Brain Project, 2023. Sex, gender and the brain: towards an inclusive research agenda. https:\/\/www.womensbrainproject.com\/wp-content\/uploads\/2023\/03\/WomensBrainProject_report_230306.pdf (accessed 13 June 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0257","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41583-024-00823-z","article-title":"The neuropathobiology of multiple sclerosis","volume":"25","author":"Woo","year":"2024","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.msard.2025.106456_bib0258","unstructured":"World Economic Forum, 2011. The global economic burden of noncommunicable diseases. https:\/\/www3.weforum.org\/docs\/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf (accessed 6 August 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0259","series-title":"Intersectoral Global Action Plan On Epilepsy and Other Neurological Disorders 2022\u20132031","year":"2023"},{"key":"10.1016\/j.msard.2025.106456_bib0260","unstructured":"World Health Organization, 2023b. Model list of essential medicines. https:\/\/iris.who.int\/bitstream\/handle\/10665\/371090\/WHO-MHP-HPS-EML-2023.02-eng.pdf?sequence=1 (accessed 19 June 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0261","unstructured":"World Health Organization, 2024. Health literacy. https:\/\/www.who.int\/teams\/health-promotion\/enhanced-wellbeing\/ninth-global-conference\/health-literacy (accessed 3 September 2024)."},{"key":"10.1016\/j.msard.2025.106456_bib0262","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/imm.13004","article-title":"Impact of sex hormones on immune function and multiple sclerosis development","volume":"156","author":"Ysrraelit","year":"2019","journal-title":"Immunology"},{"key":"10.1016\/j.msard.2025.106456_bib0263","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12961-022-00825-2","article-title":"The MULTI-ACT model: the path forward for participatory and anticipatory governance in health research and care","volume":"20","author":"Zaratin","year":"2022","journal-title":"Health Res. Policy Syst."},{"key":"10.1016\/j.msard.2025.106456_bib0264","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1407257","article-title":"The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care \u2013 updates at the 2023 plenary event","volume":"15","author":"Zaratin","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106456_bib0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577093","article-title":"Sexual dysfunction in patients with neuromyelitis optica spectrum disorder","volume":"338","author":"Zhang","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106456_bib0266","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5664\/jcsm.10304","article-title":"Sleep in multiple sclerosis: a systematic review and meta-analysis of polysomnographic findings","volume":"19","author":"Zhang","year":"2023","journal-title":"J. Clin. Sleep Med."},{"key":"10.1016\/j.msard.2025.106456_bib0267","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12974-019-1674-2","article-title":"Molecular biomarkers in multiple sclerosis","volume":"16","author":"Ziemssen","year":"2019","journal-title":"J. Neuroinflamm."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:41:52Z","timestamp":1762602112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825001981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":266,"alternative-id":["S2211034825001981"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106456","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain health \u2013 time matters: multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and related conditions. 2024 report","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106456"}}